Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

Vaccine

Volumn 30, Issue 2, 2012, Pages 329-335

  Tambyah, Paul A ^a   Wilder Smith, Annelies ^a   Pavlova, Borislava G ^b   Barrett, P Noel ^b   Oh, Helen M L ^c   Hui, David S ^d   Yuen, Kwok yung ^e   Fritsch, Sandor ^b   Aichinger, Gerald ^b   Loew Baselli, Alexandra ^b   van der Velden, Maikel ^b   Maritsch, Friedrich ^b   Kistner, Otfried ^b   Ehrlich, Hartmut J ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b BAXTER BIOSCIENCE   (Austria)

^c CHANGI GENERAL HOSPITAL   (Singapore)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Avian influenza; H5N1; Immunogenicity; Pandemic vaccine; PHASE I II; Pre pandemic vaccine; Safety

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMOLYSIS; HONG KONG; HUMAN; IMMUNOGENICITY; INDONESIA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; MYALGIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGAPORE; TREATMENT DURATION; VERO CELL; VIET NAM; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ADULT; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; HONG KONG; HUMANS; IMMUNOASSAY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; SINGAPORE; VACCINATION; VERO CELLS;

EID: 84355166474     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.088     Document Type: Article

References (31)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358(3):261-273.
2. Smith G.J., Vijaykrishna D., Ellis T.M., Dyrting K.C., Leung Y.H., Bahl J., et al. Characterization of avian influenza viruses A (H5N1) from wild birds, Hong Kong, 2004-2008. Emerg Infect Dis 2009, 15(3):402-407.
3. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO, 09 August 2011; Available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_08_31/en/index.htm.
4. Third WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. 15-16 Feb 2007; Available from: http://www.who.int/vaccine_research/diseases/influenza/meeting_150207/en/.
5. Smith G.J., Naipospos T.S., Nguyen T.D., de Jong M.D., Vijaykrishna D., Usman T.B., et al. Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam. Virology 2006, 350(2):258-268.
6. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-1351.
7. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358(24):2573-2584.
8. Chu D.W., Hwang S.J., Lim F.S., Oh H.M., Thongcharoen P., Yang P.C., et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27(52):7428-7435.
9. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27(37):5091-5095.
10. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(5):667-675.
11. Ehrlich H.J., Müller M., Fritsch S., Zeitlinger M., Berezuk G., Löw-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200(7):1113-1118.
12. Committee for Proprietary Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines 1997, European Agency for the Evaluation of Medicinal Products, London, [Publication no. CPMP/BWP/214/96].
13. Committee for Medicinal Products for Human Use (CHMP) Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application 2008, European Medicines Agency, London, [Publication no. EMEA/CPMP/VEG/4717/03-Rev. 1].
14. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16(9-10):960-968.
15. Lu B.L., Webster R.G., Hinshaw V.S. Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. Infect Immun 1982, 38(2):530-535.
16. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006, 80(10):4962-4970.
17. Schild G.C., Pereira M.S., Chakraverty P. Single-radial-haemolysis: a new method for the assay of antibody to influenza haemagglutinin. Bull World Health Organ 1975, 52:43-50.
18. Takano R., Nidom C.A., Kiso M., Muramoto Y., Yamada S., Sakai-Tagawa Y., et al. Phylogenetic characterization of H5N1 avian influenza viruses isolated in Indonesia from 2003-2007. Virology 2009, 390:13-21.
19. Landry N., Ward B.J., Trépanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010, 5:e15559.
20. Langley J.M., Frenette L., Ferguson L., Riff D., Sheldon E., Risi G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653.
21. Langley J.M., Risi G., Caldwell M., Gilderman L., Berwald B., Fogarty C., et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011, 203:1729-1738.
22. Stephenson I., Nicholson K.G., Colegate A., Podda A., Wood J., Ypma E., et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003, 21(15):1687-1693.
23. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(9540):991-997.
24. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity withan adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007, 370:580-589.
25. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442:448-452.
26. Kistner O., Howard M.K., Spruth M., Wodal W., Brühl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007, 25(32):6028-6036.
27. Lamb J.R., McMichael A.J., Rothbard J.B. T-cell recognition of influenza viral antigens. Hum Immunol 1987, 19(2):79-89.
28. Scherle P.A., Gerhard W. Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med 1986, 164(4):1114-1128.
29. Crowe B.A., Brühl P., Gerencer M., Schwendinger M.G., Pilz A., Kistner O., et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010, 29(2):166-173.
30. Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008, 3(2):e1665.
31. Keitel W., Groth N., Lattanzi M., Praus M., Hilbert A.K., Borkowski A., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28(3):840-848.